Zogenix (Zogenix) Interest Income : $0.66 Mil (TTM As of Dec. 2021)

View and export this data going back to 2010. Start your Free Trial

What is Zogenix Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Zogenix's interest income for the three months ended in Dec. 2021 was $0.08 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2021 was $0.66 Mil.

Zogenix Interest Income Historical Data

The historical data trend for Zogenix's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Interest Income Chart

Zogenix Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Interest Income

Get a 7-Day Free Trial

1.09

7.17

9.80

2.89

0.66

Zogenix Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Interest Income	Get a 7-Day Free Trial															0.39	0.31	0.19	0.09	0.08

Zogenix Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.66 Mil.

Zogenix (Zogenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608

Website

https://www.zogenix.com

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.

Executives

Erle T Mast	director	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner	director	PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick	director	C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts	director	C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar	officer: EVP & CHIEF COMMERCIAL OFFICER	C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel	officer: EVP/Chief Development Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer	officer: EVP/Chief Medical Officer	C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr	director, officer: President and CEO	[email protected] EMERYVILLE CA 94608
Mark C Wiggins	director	12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock	director	C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer	director
Shawnte Mitchell	officer: EVP, GC and Secretary	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith	officer: EVP, CFO, Treasurer & Sec.	887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5